Main menu

Fueled by a recent $15 million venture capital investment, Cambridge, Mass.-based Quanterix said it will now begin the first of what it hopes will be many clinical partnerships that use its flagship single-molecule array platform.

The financing, announced last month, was the second and final tranche of a Series A round co-led by ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. The first tranche, which closed in June 2007, was for $4 million, while the second was worth $11 million.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.